Lineage Cell Therapeutics Inc (LCTX) Actualités

OpRegen® (RG6501) Phase 1/2a Results to Be Featured at International Society for Stem Cell Research (ISSCR) 2024 Copenhagen International Symposium

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for...

Lineage Presents Preclinical Data on Its Auditory Neuronal Cell Transplant Program, ReSonance™, at the 59th Annual Inner Ear Biology Workshop

ReSonance is Manufactured by a Proprietary Process, Developed In-House, at Clinical Scale, with Relevant In-Vitro Functional Activity...

Form 4 - Statement of changes in beneficial ownership of securities

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Form 8-K - Current report

Form 8-K - Current report

Form 4 - Statement of changes in beneficial ownership of securities

Form EFFECT - Notice of Effectiveness

Form 8-K - Current report

Form 424B5 - Prospectus [Rule 424(b)(5)]

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities